IDEXX Laboratories, Inc. (IDXX) Return on Invested Capital (ROIC): 40.27%
Is IDEXX Laboratories, Inc.’s return on invested capital (ROIC) high or low?
IDEXX Laboratories, Inc.'s return on invested capital (ROIC) of 40.27% is 12% above its 5-year average of 35.94%, near the high end of its 5-year range (32.48%–41.75%).
As of Friday, June 12, 2026. 8.63% above its 12-month average of 37.07%.
IDXX Return on Invested Capital (ROIC) Chart
IDXX Average Return on Invested Capital (ROIC) Chart
IDXX Current vs Average Return on Invested Capital (ROIC) Chart
IDXX Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
40.27%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
37.07%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
34.89%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
35.94%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
31.01%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
27.20%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
25.26%
CURRENT VS TTM AVG
+8.63%
CURRENT VS 3Y AVG
+15.43%
CURRENT VS 5Y AVG
+12.06%
CURRENT VS 10Y AVG
+29.88%
CURRENT VS 15Y AVG
+48.05%
CURRENT VS 20Y AVG
+59.44%
IDXX Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IDEXX Laboratories, Inc. (IDXX) | $44.01B | 40.27% | 37.07% | 34.89% | 35.94% |
| Humana Inc. (HUM) | $44.27B | 3.12% | 3.25% | 5.37% | 7.01% |
| Agilent Technologies, Inc. (A) | $36.59B | 12.57% | 12.57% | 13.57% | 12.73% |
| Zoetis Inc. (ZTS) | $34.13B | 21.54% | 21.87% | 20.30% | 19.27% |
| Centene Corporation (CNC) | $31.37B | -13.41% | -4.17% | -0.53% | 0.76% |
| Medline Inc. (MDLN) | $30.64B | 5.69% | 6.03% | 3.95% | 3.95% |
| IQVIA Holdings Inc. (IQV) | $30.22B | 8.23% | 8.41% | 8.23% | 6.99% |
| Biogen Inc. (BIIB) | $29.52B | 6.62% | 7.71% | 8.64% | 10.90% |
| DexCom, Inc. (DXCM) | $29.04B | 16.61% | 13.40% | 11.07% | 9.62% |
| Veeva Systems Inc. (VEEV) | $26.24B | 9.48% | 9.25% | 9.54% | 11.31% |
Capital Efficiency
ROIC
40.3%
ROE
70.4%
IDEXX Laboratories, Inc. Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IDEXX Laboratories, Inc. Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for IDEXX Laboratories, Inc. (IDXX)?
- The return on invested capital (ROIC) for IDXX stock is 40.27%.
- Is IDEXX Laboratories, Inc.'s return on invested capital (ROIC) high or low?
- IDEXX Laboratories, Inc.'s return on invested capital (ROIC) of 40.27% is 12% above its 5-year average of 35.94%, near the high end of its 5-year range (32.48%–41.75%).
- What is the TTM average return on invested capital (ROIC) for IDEXX Laboratories, Inc. (IDXX)?
- The TTM average return on invested capital (ROIC) for IDXX stock is 37.07%.
- What is the 3Y average return on invested capital (ROIC) for IDEXX Laboratories, Inc. (IDXX)?
- The 3Y average return on invested capital (ROIC) for IDXX stock is 34.89%.
- What is the 5Y average return on invested capital (ROIC) for IDEXX Laboratories, Inc. (IDXX)?
- The 5Y average return on invested capital (ROIC) for IDXX stock is 35.94%.
- What is the 10Y average return on invested capital (ROIC) for IDEXX Laboratories, Inc. (IDXX)?
- The 10Y average return on invested capital (ROIC) for IDXX stock is 31.01%.
- What is the 15Y average return on invested capital (ROIC) for IDEXX Laboratories, Inc. (IDXX)?
- The 15Y average return on invested capital (ROIC) for IDXX stock is 27.20%.
- What is the 20Y average return on invested capital (ROIC) for IDEXX Laboratories, Inc. (IDXX)?
- The 20Y average return on invested capital (ROIC) for IDXX stock is 25.26%.
IDEXX Laboratories, Inc. Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 40.27% |
| 2024-12-31 | 33.87% |
| 2023-12-31 | 32.93% |
| 2022-12-31 | 32.48% |
| 2021-12-31 | 41.75% |
| 2020-12-31 | 34.32% |
| 2019-12-31 | 32.09% |
| 2018-12-31 | 34.71% |
| 2017-12-31 | 20.92% |
| 2016-12-31 | 20.02% |
| 2015-12-31 | 17.71% |
| 2014-12-31 | 17.27% |
| 2013-12-31 | 18.47% |
| 2012-12-31 | 19.73% |
| 2011-12-31 | 19.45% |
| 2010-12-31 | 19.21% |
| 2009-12-31 | 18.34% |
| 2008-12-31 | 18.94% |
| 2007-12-31 | 17.21% |
| 2006-12-31 | 21.01% |
| 2005-12-31 | 19.69% |
| 2004-12-31 | 18.24% |
| 2003-12-31 | 13.04% |
| 2002-12-31 | 12.70% |
| 2001-12-31 | 11.67% |
| 2000-12-31 | 12.39% |
| 1999-12-31 | 10.06% |
| 1998-12-31 | 9.17% |
| 1997-12-31 | -0.94% |
| 1996-12-31 | 8.50% |
Related Metrics
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Jonathan J. Mazelsky